Tenoveil
Antiretroviral
About
Tenovail® is a brand of Tenofovir alafenamide fumarate (TAF), an antiviral medication used in the treatment of HIV/AIDS and Hepatitis B virus (HBV) infections. Tenovail® is known for its greater antiviral activity and distribution into lymphoid tissues. It is approved by FDA in the treatment of HIV-1 and is often prescribed in combination with a non-nucleoside reverse transcriptase inhibitor (NNRTI). Tenovail® is a registered trademark of Carpa Healthcare limited.
Administration
Tenovail® is available in tablet form and administered orally as recommended by a physician.
Side Effects
Tenovail® may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: Diarrhea, headache, itching, fever
Contraindications
Tenoveil may cause hypersensitivity to the active substance or to any of the excipients
Hepatitis B and HIV coinfection
HIV antibody testing should be offered to all HBV infected patients whose HIV1 infection status is unknown before initiating therapy with Tenofovir Alafenamide tablets 25 mg. In patients who are coinfected with HBV and HIV, Tenofovir Alafenamide tablets 25 mg should be coadministered with other antiretroviral agents to ensure that the patient receives an appropriate regimen for treatment of HIV
Prescription Information
Tenovail® is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg). • In HBeAg positive patients without cirrhosis, treatment should be administered for at least 612 months after HBe seroconversion (HBeAg loss and HBV DNA loss with antiHBe detection) is confirmed or until HBs seroconversion or until there is loss of efficacy (see section 4.4). Regular reassessment is recommended after treatment discontinuation to detect virological relapse. • In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or until there is evidence of loss of efficacy. With prolonged treatment for more than 2 31 years, regular reassessment is recommended to confirm that continuing the selected therapy remains appropriate for the patient.
